US Patent

US11426404 — Dosing of KRAS inhibitor for treatment of cancers

Method of Use · Assigned to Amgen Inc · Expires 2040-09-15 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of administering a KRAS G12C inhibitor to a cancer subject.

USPTO Abstract

Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3306`	—	Lumakras
`U-3306`	—	Lumakras
`U-4107`	—	Lumakras

Patent Metadata

Patent number: US11426404
Jurisdiction: US
Classification: Method of Use
Expires: 2040-09-15
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.